1. Pink Sheet
  2. >>Geography
  3. >>Europe

Novartis’ Gene Therapy Luxturna Gets Routine Funding In Scotland

 
• By Eliza Slawther

Scotland’s health technology assessment body has granted routine reimbursement to Novartis’ vision loss drug Luxturna after an interim funding period via its ultra-orphan pathway, while Chiesi’s Filsuvez is set to begin its journey on the same pathway.

Rare Disease
• Source: Shutterstock

Luxturna (voretigene neparvovec), Novartis’ gene therapy for the rare vision loss disorder, retinal dystrophy, was accepted for routine use on the National Health Service by Scotland’s health technology appraisal (HTA) body, the Scottish Medicines Consortium, on 8 July.

The gene therapy was assessed under the SMC’s ultra-orphan pathway, which grants interim reimbursement to products that meet certain strict criteria while more evidence is collected to support the drugs. Luxturna was accepted onto the pathway in 2020, and the latest approval means that it will now be available on a routine basis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

UK’s International Recognition Procedure: EU Dossier Faster Than US Or Canada

 
• By Eliza Slawther

Companies that use the European Medicines Agency as a reference regulator for the UK’s International Recognition Procedure can expect a faster approval than those that use other national regulators, such as those in the US and Canada, an MHRA spokesperson has said.

FDA Use Of Artificial Intelligence Will Help US Retain Biotech Leadership

 
• By Sue Sutter and Derrick Gingery

At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.